CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
This LICENSE AGREEMENT (this "Agreement") effective as of the 9th day of June 1999, is entered into by
and between Permatec Technologie AG, a Swiss corporation having its place of business at Grienbachstrasse 17,
CH-6301 Zug, Switzerland (hereinafter referred to as "LICENSOR") and SOLVAY Pharmaceuticals B.V., a
Dutch corporation having its place of business at C. J. Van Houtenlaan 36, NL 1381 CP Weesp, The
Netherlands (hereinafter referred to as "LICENSEE"; both LICENSOR and LICENSEE hereinafter referred to
as "Party" and the "Parties", respectively).
WHEREAS, LICENSOR is a company active in the field of drug delivery and has in particular expertise in
innovative developments in the area of transdermal and transmucosal delivery routes; and
WHEREAS, LICENSOR has developed a technology platform known as Combi Gel(TM) consisting of gel
formulations combining Estradiol with a progestative as active ingredients and owns or has rights to certain
patents and owns certain proprietary know-how related to thereto; and
WHEREAS, LICENSEE is a company which markets pharmaceutical products and is interested, on the basis of
all results, data and related information made available by LICENSOR to LICENSEE, in having granted the
rights to register the Combi-Gel NETA (as defined below) in the Territory (as defined below), and upon
approval to manufacture, market, distribute and sell the Product (as defined below) in the Territory; and
WHEREAS, LICENSOR is prepared to grant to LICENSEE under the terms and conditions set forth hereafter
a license under the Patents and Know-How (both as defined below) to seek registration of the Combi-Gel
NETA in the Territory, and, upon receipt of such approval(s), to manufacture, market, distribute and sell the
Product for use and sale in the Territory.